dacomitinib + figitumumab

The combination of **dacomitinib** and **figitumumab** is an experimental therapy evaluated in early-phase clinical trials for advanced solid tumors, including non-small cell lung cancer and adenoid cystic carcinoma. **Dacomitinib** is an orally available, irreversible small molecule tyrosine kinase inhibitor that targets the HER family of receptors, including **epidermal growth factor receptor (EGFR)**, **HER2**, and **HER4**. **Figitumumab** is a monoclonal antibody directed against the **insulin-like growth factor 1 receptor (IGF-1R)**, blocking its activation and downstream signaling. The combination aims to simultaneously inhibit tumor growth signals through both the EGFR/HER and IGF-1R pathways. Early clinical trials found the regimen to be tolerable at reduced doses of both agents and demonstrated preliminary evidence of antitumor activity in tumor types such as adenoid cystic carcinoma, ovarian carcinoma, and salivary gland cancers. Figitumumab is administered intravenously, while dacomitinib is given orally. No combination-specific brand name or regulatory approval exists for this dual-agent regimen[1].

Brand names

Vizimpro (dacomitinib)dacomitinib + figitumumab

Other names

dacomitinib plus figitumumabdacomitinib and figitumumab